JESSICA GROSSMAN: Open Payments
NPI 1033974365 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$876 in 37 payments from 23 companies in 2025. Trend: 2023 $0 · 2024 $332 · 2025 $876
Food & beverage: $796Education: $80
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $142 |
| SOBI, INC | 1 | $80 |
| Novartis Pharmaceuticals Corporation | 3 | $77 |
| PharmaEssentia USA Corporation | 3 | $75 |
| Merck Sharp & Dohme LLC | 3 | $50 |
| Incyte Corporation | 2 | $44 |
| EMD Serono, Inc. | 1 | $34 |
| Aveo Pharmaceuticals, Inc. | 1 | $34 |
| Celgene Corporation | 1 | $33 |
| Genentech USA, Inc. | 1 | $32 |
Products named: BESREMI, ERLEADA, PLUVICTO, RYBREVANT, FOTIVDA, KEYTRUDA, REBLOZYL, Polivy.
Industry payments across TX — which companies pay providers there.
